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Janus-Faced Drugs:
The Double-Edged Synthetic Opiate Trade‘‘Pain has an absolute meaning,’’
says Martin Angst, Assistant Profes-
sor of Anesthesia at the Stanford
University School of Medicine. Pain
is a critical warning system, signal-
ing threats to the body. If you are
a cancer patient, pain can signal pro-
gression of disease. It is related to
your emotional and physical state;
if you are tired, pain can be much
more severe than if you are well
rested. Pain can also become a self-
propagating process or a disease
of its own, remaining long after the
original trauma is past. Chronic pain
not only threatens a person’s physi-
cal well-being but also his or her
mental health. As a consequence,
treating chronic pain without pro-
ducing side effects and drug depen-
dence is one of the more difficult
problems facing modern medicine.
A 40-min drive from Stanford’s
campus is a South San Francisco
biotech company with an intriguing
approach to the tradeoffs in pain
treatment for patients with chronic
moderate to severe pain. Pain Thera-
peutics, http://www.paintrials.com/,
founded in 1998, is developing new
opiate-based drugs that cause
fewer side effects and are less likely
to induce dependence than conven-
tional opioids. In a nod to its histori-
cal antecedents, Pain Therapeutics’
annual report is illustrated with nine-
teenth-century vignettes of opium
production and patent medicines.
Todate, the company’s threeprod-
ucts, Remoxy, Oxytrex, and PT-901
(for treating irritable bowel syn-
drome) are all in stage III clinical trials.
Remoxy and Oxytrex are being pre-
sented for broad label FDA approval.
Remoxy is a sustained-release, less
abusable form of the pain reliever
Oxycontin. Remoxy’s gel caps, de-
veloped with technology licensed
from Durect Corporation, contain
opiate formulated in a viscous gel to
absorb into the body slowly, prevent-
ing the ‘‘high’’ sensation. The pat-
ented gel also makes extraction of
oxycodone, 4,5-epoxy-14-hydroxy-
3-methoxy-17-methylmorphinan-6-one, the active ingredient by crush-
ing, chewing, or leaching it out and
concentrating it more difficult.
‘‘Treating chronic pain
without producing side
effects and drug depen-
dence is one of the more
difficult problems facing
modern medicine.’’
Oxytrex combines an extremely
low dose of naltrexone, an opiate re-
ceptor antagonist, with oxycodone.
Rat studies conducted by Pain Thera-
peutics [1] show Oxytrex has an
increased analgesic efficacy or po-
tency with decreased addictive po-
tential. According to the company’s
stage III human and animal studies,
patients are less likely to develop
tolerance to the drug, which means
they won’t have to increase the dos-
ageto get the same painrelief through
extended use. ‘‘So basically, you get
more of the analgesic effect, which is
what you want out of the opioid, with
fewerproblems,’’ saysLindsayBurns,
researcher at Pain Therapeutics.
Opium has been used by human-
kind since prehistoric times, accord-
ing to Martin Booth’s bookOpium, A
History [2]. A sample of opium was
found in the tomb of Cha in Egypt,
dating from the fifteenth century
BC. Opiate is the generic term for
a family of alkaloids that is derived
from natural opium. Modern semi-
synthetic drugs are modified opium
alkaloids. Laudanum, a tincture of
opium and alcohol, was developed
in the 1660s and stayed popular as
a sedative and medication over the
centuries. Unfortunately, it was un-
predictable in its effects because
of the variation in the relative con-
centrations of the various opiate
alkaloids in the raw opium. In the
1800s, Friedrich Wilhelm Adam Ser-
tu¨rner, a German pharmacist’s as-
sistant, looking for a more reliableremedy, isolated morphine, (5a,6a)-
7,8-didehydro-4,5-epoxy-17-methyl-
morphinan-3,6-diol, the principal
active ingredient in raw opium.
Codeine, (5a,6a)-7,8-Didehydro-4,
5-epoxy-3-methoxy-17-methylmor-
phinan-6-ol or methylmorphine, a
less powerful and less addictive
substance, was synthesized in
1832 by Robiquet followed in 1874
by British pharmacist C.R. Alder
Wright who synthesized diacetyl-
morphine, which was mass pro-
duced and marketed by Bayer under
the brand name ‘‘heroisch,’’ heroic
or heroin, at the turn of the century.
Methadone (6-[dimethylamino]-4,4-
diphenyl-3-heptanone) was synthe-
sized at I.G. Farben at Hoechst-
am-Main in Germany during World
War II. Methadone is a completely
synthetic opioid with a long-lasting
effect. It is an analgesic that is
primarily a mu-opioid receptor ago-
nist that has no resemblance to the
chemical structure of morphine
but which produces similar effects.
Oxycodone is a semi-synthetic opi-
ate analgesic in clinical use since
1917 that is pharmacodynamically
comparable to morphine. Purdue
Pharmaceuticals (Stamford, CT) pat-
ented Oxycontin, a controlled re-
lease oxycodone, in 1995, but the
formulation has been notoriously
popular with recreational abusers.
The Road to Prime Time
‘‘The pain space is something that
I’ve had my eye on since about
1985,’’ says Remy Barbier, CEO and
founder of Pain Therapeutics. ‘‘I’ve
always found it unbelievable that
the standard of care used to treat
chronic pain today is the exact same
drugs that our great-great grandpar-
ents used. I don’t understand why
huge pharmaceutical companies
with huge resources have not in-
vested in this area 50 years ago.’’
About 12 years ago, Barbier came
across research conducted at the
Albert Einstein College of Medicine
under Dr. Stanley Crain, now Profes-
sor Emeritus of the Department
Chemistry & Biology
1056of Neuroscience. Crain’s research
showed that opiates had dual prop-
erties: they not only inhibited pain,
but also had an excitatory effect that
could be mediated by a group of opi-
ate receptors.Duringchronicuse, the
excitatory effect becomes more pro-
nounced and counteracts to some
degree the pain-inhibiting ability of
the opiate. In the early 1990s, Crain’s
group went further and discovered
that by administering ultra-low doses
of naltrexone (an opiate receptor an-
tagonist) with the opiates, they could
selectively block the excitatory ef-
fects of opiates in mice while in-
creasing analgesic effects [3]. Barb-
ier thought it was ‘‘very intriguing,
but not ready for prime time.’’
Four years later, Barbier got a
phone call. Crain invited him to visit
his lab. ‘‘I flew out to New York and
spent a few days there and thought,
‘Holy cow, this guy really followed
through!’’’ Barbier recounts. With
an initial personal investment of
one million dollars, Barbier was able
to attract three rounds of venture
capital and go public. ‘‘Seven years
later, we have a pipeline of three
drugs and all are in phase III,’’ Barb-
ier says. ‘‘To deal with the two main
problems with opioids, safety and
physical dependency, we developed
Remoxy, which is a less abusable
form of a $2 billion drug. The other
drug we have, Oxytrex, is a more ef-
ficacious form of a $2 billion drug.’’
Opiates have always been a high-
risk, high-reward business, and in-
deed Pain Therapeutics’ annual re-
port states: ‘‘Drug development is
not for the impatient or impover-
ished.’’ According to its June 30,
2005, financial report, the company
has taken in $206 million in IPO and
venture money, has spent cumula-
tively $130 million, and has $81.7 mil-
lion cash and marketable securities.
Now in stage III clinical trials for its
candidates, the company is burning
about $40 million a year for research
and development and administrative
expenses. Pain Therapeutics owns
the commercial property rights to
its drug candidates, and the com-
pany is targeting the over $3 billion
pain market projected to grow as
baby boomers age.
Angst on Pain
‘‘We call opiates a double-edged
sword or Janus faced,’’ says Angst.
‘‘They do a lot of good and poten-tially a lot of harm as well.’’ Opiate
side effects include respiratory
depression, sedation, constipation,
itching, nausea, reduced function-
ing, physical dependence, and in
some cases, addiction. ‘‘More re-
cently, we have learned that opioids
somewhat paradoxically can in-
crease the sensitivity to pain,’’ says
Angst. ‘‘These side effects are more
likely to occur at higher doses.’’
According to Angst, 10 or 20
years ago opioids were predomi-
nantly prescribed only for patients
suffering from acute pain or for pal-
liative care for the dying because of
concerns about turning patients into
addicts. Angst says that most peo-
ple exposed to opiates become de-
pendent, but they do not become
addicted. ‘‘Being dependent on an
opioid means that if you don’t get
the drug you will develop signs of
withdrawal,’’ Angst says. ‘‘Being ad-
dicted means that you have an urge
to get the drug. Nicotine is actually
a much more addictive substance
than opioids.’’
‘‘The concept [behind Pain Thera-
peutics] is that a receptor can be
inhibitory or excitatory depending
on the amount of drug available at
the receptor site,’’ says Angst. ‘‘Ac-
cording to this, it makes sense to
give a very small amount of opiate
antagonist to block the excitatory
effects, thus making the opiate only
exert inhibitory effects, inhibiting
pain. However, the validity of this
concept is controversial and by no
means yet established. Studies
trying to voice this principle have
mixed results. I cannot say that the
principle they are trying to exploit
is flawed. It is a hypothesis, and I
have not seen enough scientific evi-
dence to robustly predict that the
exploited principle will work clini-
cally. Optimizing the use of opioids
is a complex undertaking. The ap-
proach pursued by Pain Therapeu-
tics is definitely innovative but lacks
broad scientific backing. It does
address something important: how
can we take advantage of the bene-
ficial effects of opiates and minimize
or avoid the [adverse] effects?’’
Opioids work so well because they
mesh into the body’s own pain sys-
tem and receptors. ‘‘Your body has
natural narcotics [endorphins]. Ev-
erybody has natural receptors in
the spinal cord and brain. People
have come up with substitutes.None are very good,’’ says Dr. Carol
A. Warfield, Chief of Anesthesia,
Critical Care and Pain Medicine at
Beth Israel Deaconess Medical Cen-
ter in Boston. ‘‘For a long time, it was
thought that if you gave people opi-
ates, they would get addicted,’’ War-
field says. ‘‘It was common for doc-
tors to under-medicate patients for
pain. 10 or 15 years ago, it became
evident that many people don’t need
an increase in opiate dosage over
time like we thought they would.’’
Currently, doctors can rotate pa-
tients between roughly three classes
of opiates to avoid tolerance or de-
pendence: the Methadone group,
the Demerol group (meperidine and
fentanyl), and the group that in-
cludes morphine and codeine. Doc-
tors also use opiate adjuncts, such
as nonsteroidal anti-inflammatories
like ibuprofen for arthritis and anti-
convulsives and antidepressants
for nerve pain. Warfield says that the
pain program uses a whole gamut of
procedures to deal with pain, includ-
ing acupuncture, hypnosis, and spi-
nal stimulators. ‘‘We tend to use opi-
ates as a last resort,’’ Warfield says.
It is now prime time for Pain Thera-
peutics. Remoxy and Oxytrexare be-
ing presented before the FDA. How-
ever, Merck’s withdrawal of Vioxx
and the FDA’s suspension of Bextra
(both COX-2 inhibitors) for clarifica-
tion of long-term side effects may
cast a shadow on FDA approval for
new pain drugs. But Pain Therapeu-
tics is using well-established drugs,
preapproved by the FDA, and put-
ting them in different formulations.
‘‘This is not a get rich quick type
of business,’’ Barbier says. ‘‘If you
are not passionate about the sci-
ence and the end points, don’t
bother. There are no shortcuts.’’
Wendy Wolfson (wendywolfson@nasw.org)
is a science technology writer based in
Oakland CA.
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